Clinical trials: Insulin Response
Dysbiosis, Endotoxemia
Gut-level Antiinflammatory Activities of Green Tea in Metabolic Syndrome
This study evaluates dietary green tea extract to improve gut health and inflammation in persons with metabolic syndrome and healthy adults.
- Conditions
- Dysbiosis, Endotoxemia, Metabolic Syndrome, Inflammation
- Trial name
- NCT03973996
- Testing
- Green Tea Extract
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Ohio State University
Obesity, Insulin Resistance
Increasing Cure Rate of Hepatitis C Therapy in Obese Hepatitis C Patients
The purpose of this study is to determine whether obese people do not respond to hepatitis C treatment as well as lean people. This research studies whether obese people will show higher sustained virologic response rate if they…
- Conditions
- Obesity, Insulin Resistance, Metabolic Syndrome, Hepatitis C
- Trial name
- NCT00871845
- Testing
- Dietary and Lifestyle modification educational sessions
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Hossam Kandil
Diabetes Mellitus, Type 2, Glucose, High Blood
Use of Functional MRI to Assess Functional Hypothalamic Activation in Response to Diazoxide
The goal of this study is to determine whether metabolic control centers in the brain can be activated in patients with type 2 diabetes (T2D) as compared to non-diabetic individuals.
- Conditions
- Diabetes Mellitus, Type 2, Glucose, High Blood, Glucose Metabolism Disorders (Including Diabetes Mellitus)
- Trial name
- NCT03566511
- Testing
- Diazoxide
- Where
- United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Meredith Hawkins
Type 1 Diabetes, Type 1 Diabetes Mellitus With Hypoglycemia
Maximising Time With a Normal Blood Glucose to Restore the Glucagon Response in Type 1 Diabetes
Almost all people who have had type 1 diabetes for 5 years have a defect in secretion of the hormone Glucagon. This hormone is involved in the body's response to low blood glucose (hypoglycaemia).
- Conditions
- Type 1 Diabetes, Type 1 Diabetes Mellitus With Hypoglycemia, Hypoglycemia, Hypoglycemia Unawareness
- Trial name
- NCT04614168
- Testing
- Stepped hyperinsulinaemic-hypoglycaemic clamp study, Insulin pump, Continuous glucose monitor
- Where
- United Kingdom
- Volunteers
- 24 people
- Sponsor
- University of Edinburgh
Type 1 Diabetes Mellitus
Physiologic Response to Glucagon at Varying Insulin Levels
The purpose of this research study is to test how different levels of insulin block the effect of glucagon. Insulin is a hormone that lowers blood glucose. Glucagon raises blood glucose.
- Trial name
- NCT01483651
- Testing
- Glucagon, Insulin
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Legacy Health System
Primary Biliary Cirrhosis
Study of Abatacept (Orencia) to Treat Primary Biliary Cirrhosis
The purpose of this study is to determine if abatacept (Orencia) is effective in patients with primary biliary cirrhosis who do not respond adequately to standard treatment with ursodeoxycholic acid (UDCA, Urso, Ursodiol…
- Trial name
- PBC (NCT02078882)
- Testing
- abatacept
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Christopher Bowlus, MD
Pharmacodynamic Response to Small Doses of Insulin
Transdermal Insulin Response In Healthy Volunteers
Bio-fermentation produced Human insulin is available without prescription in the U.S. This study is a physician-initiated trial of a formula enabling transdermal delivery of human insulin.
- Trial name
- NCT04857320
- Testing
- Human insulin
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Transdermal Delivery Solutions Corp
Healthy, Natriuretic Peptides
Racial Differences in the Natriuretic Peptide Response to Glucose Challenge
The purpose of the study is to discover any racial dissimilarity in the response of Natriuretic peptide (NP) system to acute metabolic influences such as a high carbohydrate challenge
- Conditions
- Healthy, Natriuretic Peptides, Metabolic Syndrome
- Trial name
- NCT03072602
- Testing
- Study diet, Glucose Challenge
- Where
- United States
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Type 2 Diabetes Mellitus
Efficacy Study of Pioglitazone and Metformin and Association Between Pioglitazone Response and Peroxisome Proliferator-activated Receptor Gamma Gene Variants in Bangladeshi Type 2 Diabetes Mellitus Subjects
The present study was undertaken to assess the efficacy and safety of two different insulin sensitizers (namely Pioglitazone and Metformin) among subjects with type 2 diabetes mellitus (T2DM) in Bangladesh.
- Trial name
- T2DMCT (NCT01589445)
- Testing
- Pioglitazone hydrochloride, Metformin hydrochloride
- Where
- Bangladesh
- Volunteers
- 77 people
- Sponsor
- University of Dhaka
Diabetes Mellitus, Type 1
A Study to Compare and Measure the Effects of Insulin Peglispro (LY2605541) and Glargine on Meal Time Insulin Requirements
This study will look into how a base dose of insulin peglispro and insulin glargine will affect the meal time dose and efficacy of insulin lispro in type 1 diabetics.
- Trial name
- NCT02152384
- Testing
- Insulin Peglispro, Insulin Lispro, Insulin Glargine
- Where
- Germany
- Volunteers
- 28 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
Effect of LY2189265 on Insulin Secretion in Response to Intravenous Glucose
The purpose of this study is to measure the effect of LY2189265 to increase insulin levels in response to glucose intake.
- Trial name
- NCT01300260
- Testing
- LY2189265, Insulin, Glucose
- Where
- Germany
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
Liquid Meal Study With Insulin Lispro With/Without Recombinant Human Hyaluronidase PH20 (rHuPH20) and Regular Human Insulin With rHuPH20 to Compare Pharmacokinetics, Postprandial Glycemic Response, and Optimal Insulin Dose in Participants With Type 2 Diabetes Mellitus (T2DM)
This is a single-center, Phase 2, randomized, double-blind, 3-way crossover meal study in participants with Type 2 Diabetes Mellitus (T2DM) to determine the optimum dose and compare the pharmacokinetics (PK) and postprandial…
- Trial name
- NCT00916357
- Testing
- Humalog, Humulin-R, Recombinant human hyaluronidase PH20 (rHuPH20)
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Halozyme Therapeutics
Type 1 Diabetes, Hyperglycemia, Postprandial
Glucagon Response to Prandial Insulin Administration in Persons With Type 1 Diabetes
Glucagon regulation and response in persons with T1D at the basal state and in response to various stimuli remains unclear. Dr. Philip Cryer has previously reported that, in T1D young adults with a course of the disease of 16+9…
- Trial name
- NCT04079881
- Testing
- Insulin
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Washington University School of Medicine
Insulin Resistance, Diabetes
Acute Effect of HP-211 (Axulin) on Blood Glucose and Serum Insulin Responses in Healthy Lean and Overweight Humans
Blood sugar levels are controlled by insulin, a hormone made by cells in the pancreas. After a meal, carbohydrates are broken down into glucose (blood sugar) which is absorbed from the intestine into the blood leading to a rise…
- Trial name
- NCT03135015
- Testing
- 2g capsules, 4g capsules, Water Control
- Where
- Canada
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Housey Healthcare ULC
Type 1 Diabetes Mellitus
A Study of How Insulin Peglispro (LY2605541) and Insulin Glargine Affect the Breakdown of Fat and Sugar in Type 1 Diabetics
This is a two-period study of participants with type 1 diabetes mellitus (T1DM). In each period, participants will receive once daily injections of stable dose LY2605541 or insulin glargine for 28 to 35 days followed by…
- Trial name
- NCT01925989
- Testing
- LY2605541, Insulin Glargine
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Diabetes
GLP1R Polymorphisms and Response to GLP1
Glucagon-like Peptide-1 (GLP-1) is an important incretin hormone which acts as a powerful insulin secretagogue. Defects in GLP-1 synthesis and secretion are thought to be part of the pathogenesis of type 2 diabetes.
- Trial name
- NCT00588380
- Testing
- GLP-1
- Where
- United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Insulin Resistance, Type 2 Diabetes Mellitus
T-IR- Study to Understand the Effects of Testosterone and Estrogen on the Body's Response to the Hormone Insulin
The purpose of this research study is to understand the effects of testosterone and estrogen on the body's response to the hormone insulin.
- Conditions
- Insulin Resistance, Type 2 Diabetes Mellitus, Obesity, Androgen Deficiency
- Trial name
- T-IR (NCT01686828)
- Testing
- Acyline, Testosterone 1.62% gel, Letrozole
- Where
- United States
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- University of Washington
Type 1 Diabetes Mellitus
Phase II Pharmacokinetics Study of Humalog and Humulin-R With and Without rHuPH20 in Type 1 Diabetes Mellitus
Humalog and Humulin-R (recombinant human insulin) are Food and Drug Administration (FDA) approved medications for the treatment of diabetes mellitus.
- Trial name
- NCT00774800
- Testing
- Humalog, Humulin-R, Recombinant human hyaluronidase PH20 (rHuPH20)
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Halozyme Therapeutics
Sleep Apnea Syndromes, Inflammation
The Effects of Obesity and Obstructive Sleep Apnea on Inflammation and Heart Disease
Obstructive sleep apnea (OSA) is a serious sleep disorder in which a person's breathing is restricted during sleep. Obese individuals with OSA are at an increased risk of inflammation and heart conditions, but it is unknown…
- Trial name
- NCT00371293
- Testing
- Weight Loss Program, CPAP therapy
- Where
- 2 sites in United States
- Volunteers
- 181 people
- Sponsor
- University of Pennsylvania
Hypoglycemia Unawareness, Diabetes Mellitus, Type 1
Glucagon Infusion in T1D Patients With Recurrent Severe Hypoglycemia: Effects on Counter-Regulatory Responses
This is a prospective, randomized, controlled, double-blind, parallel 4-group trial with the primary analysis after 4 weeks of treatment with continuous subcutaneous glucagon infusion (CSGI) or placebo.
- Trial name
- NCT03490942
- Testing
- Glucagon
- Where
- 5 sites in United States
- Volunteers
- 49 people
- Sponsor
- Xeris Pharmaceuticals